Literature DB >> 29035169

Prospective Longitudinal Substance Use Patterns in Patients Preparing for Hepatitis C Treatment.

Carol S North1, David E Pollio2, Omar T Sims2, Mamta K Jain3, Barry A Hong4.   

Abstract

OBJECTIVES: This study prospectively examined the independent courses of alcohol, drugs, and smoking over 18 months in 154 patients preparing for hepatitis C virus (HCV) treatment in relation to functioning, negative coping, and satisfaction with quality of life in data collected from a randomized controlled trial of multiple-family group psychoeducation for patients preparing for HCV treatment. Patients with HCV who had consistent abstinence, consistent use, or achievement of abstinence after study entry were examined for outcomes pertaining to functioning in the context of HCV, negative coping, and satisfaction with quality of life.
METHODS: Of 309 patients considering treatment for HCV recruited from outpatient clinics at two major university medical centers and a Veterans Affairs medical center for a randomized controlled trial of a psychoeducation intervention, 154 completed baseline, 6-month, and 18-month assessments. The assessments included structured diagnostic interviews; questionnaires examining functioning, coping, and satisfaction with quality of life; medical record review; and urine testing for substances of abuse. For these analyses, substance use patterns were determined as consistent abstinence, consistent use, and achieving abstinence after study entry for alcohol and drug use and smoking.
RESULTS: The entire sample generally improved in all of these three outcomes over the course of the study. The course of alcohol, drugs, and smoking predicted HCV-related functioning, negative coping, and satisfaction with quality-of-life outcomes over 18 months. Three specific patterns of use (consistent abstinence, consistent use, and achievement of abstinence after study entry) of these substances diverged in association with outcomes related to functioning, negative coping, and satisfaction with quality of life, not only across trajectories over time within substance types but also among types of substances.
CONCLUSIONS: This study's finding that different substances were associated with distinct clinical outcomes suggests the need to conceptually unbundle different types of substances in managing HCV. Future research is needed to examine the clinical utility of further unbundling these substances and also to further investigate effects of various amounts of use of these substances.

Entities:  

Keywords:  Hepatitis C; alcohol; coping; drugs; functioning; longitudinal; prospective; quality of life; substance use; tobacco

Mesh:

Year:  2018        PMID: 29035169      PMCID: PMC6072267          DOI: 10.1080/15504263.2017.1380246

Source DB:  PubMed          Journal:  J Dual Diagn        ISSN: 1550-4271


  27 in total

1.  Personality, Coping, and Well-Being for People Living with Chronic Hepatitis C.

Authors:  Douglas F Cellar; Devon Voster; Rachel Fetters; Emily Twitchell; Gary W Harper; Cotler Scott
Journal:  Psychol Rep       Date:  2016-04

2.  Association of Hepatitis C Virus With Alcohol Use Among U.S. Adults: NHANES 2003-2010.

Authors:  Amber L Taylor; Maxine M Denniston; R Monina Klevens; Lela R McKnight-Eily; Ruth B Jiles
Journal:  Am J Prev Med       Date:  2016-05-10       Impact factor: 5.043

3.  An assessment of concurrent drug and alcohol use among patients seeking treatment for hepatitis C.

Authors:  Omar T Sims; David E Pollio; Barry A Hong; Mamta K Jain; Geri R Brown; Carol S North
Journal:  Ann Clin Psychiatry       Date:  2016-02       Impact factor: 1.567

4.  Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention.

Authors:  Lydia N Drumright; Holly Hagan; David L Thomas; Mary H Latka; Elizabeth T Golub; Richard S Garfein; John D Clapp; Jennifer V Campbell; Sebastian Bonner; Farzana Kapadia; Thelma King Thiel; Steffanie A Strathdee
Journal:  J Hepatol       Date:  2010-11-24       Impact factor: 25.083

5.  Altered quality of life in the early stages of chronic hepatitis C is due to the virus itself.

Authors:  Edna Strauss; Francisco Augusto Porto-Ferreira; Cesar de Almeida-Neto; Maria Cristina Dias Teixeira
Journal:  Clin Res Hepatol Gastroenterol       Date:  2013-11-14       Impact factor: 2.947

6.  Can tobacco use promote HCV-induced miR-122 hijacking and hepatocarcinogenesis?

Authors:  Lijun Zhao; Farong Li; Ethan Will Taylor
Journal:  Med Hypotheses       Date:  2012-12-05       Impact factor: 1.538

7.  Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.

Authors:  Anna S Lok; Leonard B Seeff; Timothy R Morgan; Adrian M di Bisceglie; Richard K Sterling; Teresa M Curto; Gregory T Everson; Karen L Lindsay; William M Lee; Herbert L Bonkovsky; Jules L Dienstag; Marc G Ghany; Chihiro Morishima; Zachary D Goodman
Journal:  Gastroenterology       Date:  2008-09-18       Impact factor: 22.682

Review 8.  Behavioral Interventions to Reduce Alcohol Use Among Patients with Hepatitis C: A Systematic Review.

Authors:  Omar T Sims; Quentin R Maynard; Pam A Melton
Journal:  Soc Work Public Health       Date:  2016-06-13

9.  Independent and additive interactive effects among tumor necrosis factor-alpha polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Huey-Ru Tsai; Lee-Yea Chuang; Jung-Fa Tsai; Zu-Yau Lin; Min-Yuh Hsieh; Shin-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Ming-Lung Yu; Chia-Yen Dai; Jan-Gowth Chang
Journal:  Medicine (Baltimore)       Date:  2009-11       Impact factor: 1.889

Review 10.  Hepatitis C, innate immunity and alcohol: friends or foes?

Authors:  Natalia A Osna; Murali Ganesan; Kusum K Kharbanda
Journal:  Biomolecules       Date:  2015-02-05
View more
  1 in total

1.  A Systematic Comparison of African American and Non-African American Patients on Psychosocial Aspects of Hepatitis C Infection.

Authors:  Omar T Sims; Barry A Hong; Shaonin Ji; David E Pollio; Carol S North
Journal:  J Relig Health       Date:  2018-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.